CoChat

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

Open access
Kato, Shunsuke, Iida, Satoru, Higuchi, Tetsuro, Ishikawa, Toshiaki, Takagi, Yoko, Yasuno, Masamichi, Enomoto, Masayuki, Uetake, Hiroyuki, Sugihara, Kenichi · 2007 · International Journal of Cancer
Cited by 141

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The PI3K‐AKT pathway is activated in a variety of human cancers, resulting in disturbance of cell growth, proliferation and survival. Among the factors affecting the pathway, the K‐Ras mutation and PIK3CA mutation are the most common oncogenic alterations in colorectal cancer. We hypothesized that these two mutations are important in activation of the PI3K pathway and colorectal carcinogenesis. In this study, we aimed to examine the influence of PIK3CA mutation and K‐Ras mutation on AKT activation, and to clarify whether PIK3CA mutation,K‐Ras mutation and p‐AKT expression may be used as parameters for predicting prognosis in colorectal cancer. Tissue samples from 158 colorectal cancer patients who underwent surgical resection were examined. The sequences of exon 1 of K‐Ras and exons 9 and 20 of PIK3CA were determined by direct sequencing using genomic DNA extracted from paraffin‐embedded blocks. Activation status of AKT was evaluated by immunohistochemical staining using phospho‐specific AKT antibody (Ser473). Correlation between these factors and clinicopathologic findings/patient survival were examined. As a result,PIK3CA mutation was significantly associated with shorter relapse‐free survival (RFS) in stage II/III patients (p= 0.0216) and shorter disease‐specific survival in all patients (p= 0.0357). In the multivariate analysis,PIK3CA mutation was the only independent and significant prognostic factor for RFS in stage II/III patients (p= 0.0433, HR 2.478). This study revealed the prognostic value of PIK3CA mutation in colorectal cancer patients. Patients with PIK3CA mutation should be followed up carefully. Moreover, our result suggests that inhibition of PIK3CA mutant may be a new molecular target therapy. © 2007 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.22890

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 141

Metadata

Authors
Kato, S., Iida, S., Higuchi, T., Ishikawa, T., Takagi, Y., Yasuno, M., Enomoto, M., Uetake, H., & Sugihara, K.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2007-08-14
Volume
121
Issue
8
Pages
1771-1778
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2046787687
Cited by
141
References
7
FWCI
3.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. https://app.cochat.ai/papers/10.1002/ijc.22890
The paper
Kato, S., Iida, S., Higuchi, T., Ishikawa, T., Takagi, Y., Yasuno, M., Enomoto, M., Uetake, H., & Sugihara, K. (2007). PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.22890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.